Monte Rosa Therapeutics (GLUE) said Monday that the first patients have been dosed in its phase 1 study of MRT-8102 for the treatment of multiple inflammatory diseases.
The study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers, the company said.
Monte Rosa said it expects the initial results of the study in H1 of 2026.
The company's shares were up 6.2% in premarket activity on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。